The Post-Mayo World Of Life Sciences Patents

In this three-part series, we will look at how the U.S. Supreme Court’s jurisprudence on patent eligibility has evolved, examine the impact of its March 2012 decision in Mayo Collaborative Services v. Prometheus Labs, Inc. on life sciences patent litigation in lower courts, and discuss what it means for patent eligibility of biologic and biosimilar patents. Read Limin Zheng’s article published in Biosimilar Development: Part 1; Part 2; Part 3.



Leave a Reply

Your email address will not be published. Required fields are marked *